{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:16:50Z","timestamp":1773249410139,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T00:00:00Z","timestamp":1520380800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Natural Science Fund","award":["81070257"],"award-info":[{"award-number":["81070257"]}]},{"DOI":"10.13039\/501100012245","name":"Science and Technology Planning Project of Guangdong Province","doi-asserted-by":"crossref","award":["2014A020212481"],"award-info":[{"award-number":["2014A020212481"]}],"id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s40256-018-0270-7","type":"journal-article","created":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T08:11:28Z","timestamp":1520410288000},"page":"271-282","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Comparative Effectiveness of Inclisiran 100, 300, and 500\u00a0mg in a Population with Hyperlipidemia: A Network Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"18","author":[{"given":"Yang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinsong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,7]]},"reference":[{"key":"270_CR1","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.clinthera.2009.02.017","volume":"31","author":"PJ Delahoy","year":"2009","unstructured":"Delahoy PJ, Magliano DJ, Webb K, et al. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. Clin Ther. 2009;31:236\u201344.","journal-title":"Clin Ther"},{"key":"270_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3810\/pgm.2013.01.2620","volume":"125","author":"JJ DiNicolantonio","year":"2013","unstructured":"DiNicolantonio JJ, Lavie CJ, Serebruany VL, Serebruany VL, O\u2019Keefe JH, O\u2019Keefe JH. Statin wars: the heavyweight match\u2013atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease. Postgrad Med. 2013;125:7\u201316.","journal-title":"Postgrad Med"},{"key":"270_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3810\/pgm.2014.01.2722","volume":"126","author":"PC Deedwania","year":"2014","unstructured":"Deedwania PC. Statins in chronic kidney disease: cardiovascular risk and kidney function. Postgrad Med. 2014;126:29\u201336.","journal-title":"Postgrad Med"},{"key":"270_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2143\/AC.63.2.2029534","volume":"63","author":"J Ducobu","year":"2008","unstructured":"Ducobu J, Scheen A, Van Gaal L, et al. Belgian expert opinion: how to reduce the residual risk in atherogenic dyslipidaemic patients: place of fibrates. Acta Cardiol. 2008;63:235\u201348.","journal-title":"Acta Cardiol"},{"issue":"37","key":"270_CR5","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/eurheartj\/ehw046","volume":"1","author":"PM Ridker","year":"2016","unstructured":"Ridker PM, Mora S, Rose L. Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur Heart J. 2016;1(37):1373\u20139.","journal-title":"Eur Heart J"},{"key":"270_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1185\/03007995.2013.766592","volume":"29","author":"Q Geng","year":"2013","unstructured":"Geng Q, Ren J, Chen H, et al. Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2013;29:181\u20138.","journal-title":"Curr Med Res Opin"},{"key":"270_CR7","doi-asserted-by":"publisher","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","volume":"158","author":"H Zhang","year":"2013","unstructured":"Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158:526\u201334.","journal-title":"Ann Intern Med"},{"key":"270_CR8","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1185\/03007990802469102","volume":"24","author":"K Tziomalos","year":"2008","unstructured":"Tziomalos K, Athyros VG, Athyros VG, Mikhailidis DP, Mikhailidis DP. Statin discontinuation: an underestimated risk? Curr Med Res Opin. 2008;24:3059\u201362.","journal-title":"Curr Med Res Opin"},{"issue":"354","key":"270_CR9","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"23","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley THJ, Mosley TH Jr, Hobbs HH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;23(354):1264\u201372.","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"270_CR10","doi-asserted-by":"publisher","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","volume":"50","author":"JD Horton","year":"2009","unstructured":"Horton JD, Cohen JC, Hobbs HH, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res. 2009;50(Suppl):S172\u20137.","journal-title":"J Lipid Res"},{"issue":"105","key":"270_CR11","doi-asserted-by":"publisher","first-page":"11915","DOI":"10.1073\/pnas.0805434105","volume":"19","author":"M Frank-Kamenetsky","year":"2008","unstructured":"Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA. 2008;19(105):11915\u201320.","journal-title":"Proc Natl Acad Sci USA."},{"key":"270_CR12","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489\u201399.","journal-title":"N Engl J Med"},{"key":"270_CR13","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500\u20139.","journal-title":"N Engl J Med"},{"key":"270_CR14","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.jacc.2012.08.986","volume":"60","author":"CS Dias","year":"2012","unstructured":"Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol. 2012;60:1888\u201398.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"270_CR15","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1056\/NEJMc1703361","volume":"376","author":"K Fitzgerald","year":"2017","unstructured":"Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. New Engl J Med. 2017;376(18):e38.","journal-title":"New Engl J Med."},{"key":"270_CR16","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.amjcard.2015.02.006","volume":"115","author":"CM Ballantyne","year":"2015","unstructured":"Ballantyne CM, Neutel J, Cropp A, Duggan W, Wang EQ, Plowchalk D, Sweeney K, Kaila N, Vincent J, Bays H. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin\/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol. 2015;115:1212\u201321.","journal-title":"Am J Cardiol"},{"key":"270_CR17","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","volume":"376","author":"KK Ray","year":"2017","unstructured":"Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, Hall T, Troquay RPT, Turner T, Visseren FLJ, Wijngaard P, Wright RS, Kastelein JJP. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. New Engl J Med. 2017;376:1430\u201340.","journal-title":"New Engl J Med."},{"issue":"7","key":"270_CR18","doi-asserted-by":"publisher","first-page":"404","DOI":"10.4330\/wjc.v7.i7.404","volume":"26","author":"R DuBroff","year":"2015","unstructured":"DuBroff R, de Lorgeril M. Cholesterol confusion and statin controversy. World J Cardiol. 2015;26(7):404\u20139.","journal-title":"World J Cardiol."},{"key":"270_CR19","first-page":"178","volume":"3","author":"SK Rao","year":"2011","unstructured":"Rao SK, Prasad T, Mohanta GP, et al. An overview of statins as hypolipidemic drugs. Int J Pharm Sci Drug Res. 2011;3:178.","journal-title":"Int J Pharm Sci Drug Res."},{"key":"270_CR20","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","volume":"370","author":"S Lewington","year":"2007","unstructured":"Lewington S, Whitlock G, Whitlock G, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370:1829\u201339.","journal-title":"Lancet"},{"key":"270_CR21","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/j.amjcard.2005.07.079","volume":"96","author":"M Clearfield","year":"2005","unstructured":"Clearfield M, Downs JR, Lee M, et al. Implications from the Air Force\/Texas Coronary Atherosclerosis Prevention Study for the Adult Treatment Panel III guidelines. Am J Cardiol. 2005;96:1674\u201380.","journal-title":"Am J Cardiol"},{"key":"270_CR22","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s10557-016-6680-3","volume":"30","author":"LD Colantonio","year":"2016","unstructured":"Colantonio LD, Kent ST, Huang L, Chen L, Monda KL, Serban MC, Manthripragada A, Kilgore ML, Rosenson RS, Muntner P. Algorithms to identify statin intolerance in medicare administrative claim data. Cardiovasc Drugs Ther. 2016;30:525\u201333.","journal-title":"Cardiovasc Drugs Ther"},{"key":"270_CR23","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/pds.3787","volume":"24","author":"JM Franklin","year":"2015","unstructured":"Franklin JM, Krumme AA, Tong AY, Shrank WH, Matlin OS, Brennan TA, Choudhry NK. Association between trajectories of statin adherence and subsequent cardiovascular events. Pharmacoepidemiol Drug Saf. 2015;24:1105\u201313.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"388","key":"270_CR24","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","volume":"19","author":"R Collins","year":"2016","unstructured":"Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;19(388):2532\u201361.","journal-title":"Lancet"},{"key":"270_CR25","doi-asserted-by":"crossref","unstructured":"Banach M, Stulc T, Dent R, Toth PP. Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement. Int J CARDIOL. 2016; 15;225:184\u201396.","DOI":"10.1016\/j.ijcard.2016.09.075"},{"key":"270_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0140-6736(13)61914-5","volume":"383","author":"K Fitzgerald","year":"2014","unstructured":"Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet. 2014;383:60\u20138.","journal-title":"Lancet"},{"key":"270_CR27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1124\/jpet.114.221242","volume":"353","author":"KR Henne","year":"2015","unstructured":"Henne KR, Ason B, Howard M, et al. Anti-PCSK9 antibody pharmacokinetics and low-density lipoprotein-cholesterol pharmacodynamics in nonhuman primates are antigen affinity-dependent and exhibit limited sensitivity to neonatal Fc receptor-binding enhancement. J Pharmacol Exp Ther. 2015;353:119\u201331.","journal-title":"J Pharmacol Exp Ther"},{"key":"270_CR28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/bs.acc.2015.10.005","volume":"73","author":"EE Egom","year":"2016","unstructured":"Egom EE, Hafeez H. Biochemistry of statins. Adv Clin Chem. 2016;73:127\u201368.","journal-title":"Adv Clin Chem"},{"key":"270_CR29","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1194\/jlr.M700437-JLR200","volume":"49","author":"HE Careskey","year":"2008","unstructured":"Careskey HE, Davis RA, Alborn WE, et al. Atorvastatin increases human serum levels of proprotein convertase subtilisin\/kexin type 9. J Lipid Res. 2008;49:394\u20138.","journal-title":"J Lipid Res"},{"key":"270_CR30","first-page":"163","volume":"120","author":"J Davignon","year":"2009","unstructured":"Davignon J, Dubuc G. Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels. Trans Am Clin Climatol Assoc. 2009;120:163\u201373.","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"270_CR31","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.atherosclerosis.2010.05.027","volume":"212","author":"P Costet","year":"2010","unstructured":"Costet P, Hoffmann MM, Cariou B, et al. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis. 2010;212:246\u201351.","journal-title":"Atherosclerosis."},{"key":"270_CR32","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1194\/jlr.M008144","volume":"51","author":"G Welder","year":"2010","unstructured":"Welder G, Zineh I, Pacanowski MA, et al. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res. 2010;51:2714\u201321.","journal-title":"J Lipid Res"},{"key":"270_CR33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.pharmthera.2016.11.001","volume":"170","author":"M Banach","year":"2017","unstructured":"Banach M, Rizzo M, Nikolic D, Howard G, Howard V, Mikhailidis D. Intensive LDL-Cholesterol lowering therapy and neurocognitive function. Pharmacol Ther. 2017;170:181\u201391.","journal-title":"Pharmacol Ther"},{"key":"270_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5114\/aoms.2015.49807","volume":"11","author":"M Banach","year":"2015","unstructured":"Banach M, Rizzo M, Toth PP, et al. Statin intolerance-an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015;11:1\u201323.","journal-title":"Arch Med Sci."},{"key":"270_CR35","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.jacc.2017.07.752","volume":"70","author":"RS Rosenson","year":"2017","unstructured":"Rosenson RS, Baker S, Banach M, et al. Optimizing cholesterol treatment in patients with muscle complaints. J Am Coll Cardiol. 2017;70:1290\u2013301.","journal-title":"J Am Coll Cardiol"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-018-0270-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-018-0270-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-018-0270-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T03:30:47Z","timestamp":1589859047000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-018-0270-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,7]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["270"],"URL":"https:\/\/doi.org\/10.1007\/s40256-018-0270-7","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,7]]},"assertion":[{"value":"7 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by the National Natural Science Fund (grant no. 81070257) and the Science and Technology Planning Project of Guangdong Province (grant no. 2014A020212481).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Yang Wang, Jinsong Wang, and Shenming Wang have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}